These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 27369643

  • 1. Immunogenicity of tocilizumab in patients with rheumatoid arthritis.
    Sigaux J, Hamze M, Daien C, Morel J, Krzysiek R, Pallardy M, Maillere B, Mariette X, Miceli-Richard C.
    Joint Bone Spine; 2017 Jan; 84(1):39-45. PubMed ID: 27369643
    [Abstract] [Full Text] [Related]

  • 2. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
    Stubenrauch K, Wessels U, Birnboeck H, Ramirez F, Jahreis A, Schleypen J.
    Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
    [Abstract] [Full Text] [Related]

  • 3. A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis.
    Saito S, Suzuki K, Yoshimoto K, Kaneko Y, Matsumoto Y, Yamaoka K, Takeuchi T.
    Arthritis Res Ther; 2017 Oct 17; 19(1):231. PubMed ID: 29041951
    [Abstract] [Full Text] [Related]

  • 4. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
    Shimamoto K, Ito T, Ozaki Y, Amuro H, Tanaka A, Nishizawa T, Son Y, Inaba M, Nomura S.
    J Rheumatol; 2013 Jul 17; 40(7):1074-81. PubMed ID: 23637318
    [Abstract] [Full Text] [Related]

  • 5. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.
    Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A, Dimonaco S, Mitchell N.
    Ann Rheum Dis; 2016 Jun 17; 75(6):1081-91. PubMed ID: 26511996
    [Abstract] [Full Text] [Related]

  • 6. Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study.
    Kneepkens EL, van den Oever I, Plasencia CH, Pascual-Salcedo D, de Vries A, Hart M, Nurmohamed MT, Balsa A, Rispens T, Wolbink G.
    Scand J Rheumatol; 2017 Mar 17; 46(2):87-94. PubMed ID: 27440258
    [Abstract] [Full Text] [Related]

  • 7. Sustained Response Following Discontinuation of Methotrexate in Patients With Rheumatoid Arthritis Treated With Subcutaneous Tocilizumab: Results From a Randomized, Controlled Trial.
    Kremer JM, Rigby W, Singer NG, Birchwood C, Gill D, Reiss W, Pei J, Michalska M.
    Arthritis Rheumatol; 2018 Aug 17; 70(8):1200-1208. PubMed ID: 29575803
    [Abstract] [Full Text] [Related]

  • 8. Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response.
    Kikuchi J, Hashizume M, Kaneko Y, Yoshimoto K, Nishina N, Takeuchi T.
    Arthritis Res Ther; 2015 Jan 21; 17(1):10. PubMed ID: 25604867
    [Abstract] [Full Text] [Related]

  • 9. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
    Sagawa A.
    Mod Rheumatol; 2011 Aug 21; 21(4):352-8. PubMed ID: 21347804
    [Abstract] [Full Text] [Related]

  • 10. Association of Serum Tocilizumab Trough Concentrations with Clinical Disease Activity Index Scores in Adult Patients with Rheumatoid Arthritis.
    Arad U, Elkayam O.
    J Rheumatol; 2019 Dec 21; 46(12):1577-1581. PubMed ID: 31154416
    [Abstract] [Full Text] [Related]

  • 11. Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs oranti-tumor necrosis factor.
    Abdulkader OAF, Qushmaq K, Aljishi F.
    Ann Saudi Med; 2016 Dec 21; 36(3):190-6. PubMed ID: 27236390
    [Abstract] [Full Text] [Related]

  • 12. Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.
    Burmester GR, Choy E, Kivitz A, Ogata A, Bao M, Nomura A, Lacey S, Pei J, Reiss W, Pethoe-Schramm A, Mallalieu NL, Wallace T, Michalska M, Birnboeck H, Stubenrauch K, Genovese MC.
    Ann Rheum Dis; 2017 Jun 21; 76(6):1078-1085. PubMed ID: 28007755
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.
    Suzuki T, Horikoshi M, Sugihara M, Hirota T, Ogishima H, Umeda N, Kondo Y, Tsuboi H, Hayashi T, Chino Y, Matsumoto I, Sumida T.
    Mod Rheumatol; 2013 Jul 21; 23(4):782-7. PubMed ID: 22975733
    [Abstract] [Full Text] [Related]

  • 14. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
    Avdeeva AS, Aleksandrova EN, Novikov AA, Cherkasova MV, Panasyuk EY, Nasonov EL.
    Ter Arkh; 2013 Jul 21; 85(5):24-9. PubMed ID: 23819335
    [Abstract] [Full Text] [Related]

  • 15. Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index.
    Kawashiri SY, Kawakami A, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, Yamasaki S, Nakamura H, Ueki Y, Migita K, Mizokami A, Origuchi T, Aoyagi K, Eguchi K.
    Mod Rheumatol; 2011 Aug 21; 21(4):365-9. PubMed ID: 21229375
    [Abstract] [Full Text] [Related]

  • 16. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate.
    Nakashima Y, Kondo M, Harada H, Horiuchi T, Ishinishi T, Jojima H, Kuroda K, Miyahara H, Nagamine R, Nakashima H, Otsuka T, Saikawa I, Shono E, Suematsu E, Tsuru T, Wada K, Iwamoto Y.
    Mod Rheumatol; 2010 Aug 21; 20(4):343-52. PubMed ID: 20480201
    [Abstract] [Full Text] [Related]

  • 17. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation.
    Chen LF, Mo YQ, Jing J, Ma JD, Zheng DH, Dai L.
    Int J Rheum Dis; 2017 Jul 21; 20(7):859-869. PubMed ID: 28160426
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of extending intravenous tocilizumab intervals from 4 to 6 weeks in rheumatoid arthritis patients with good response to 4-week intervals.
    Saiki O, Uda H.
    Rheumatol Int; 2018 Dec 21; 38(12):2307-2313. PubMed ID: 30206670
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.